NANJING, China, Oct. 27 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today its participation in the Goldman Sachs China Investment Frontier Conference 2008. The conference will be held at the Grand Hyatt Beijing hotel on November 3-4, 2008.
Simcere's chief executive officer, Jinsheng Ren, chief financial officer, Frank Zhigang Zhao, and vice president of marketing, Mark Chen, will attend the conference on Thursday November 4. Jinsheng Ren will speak at the Track I Panel session headlined Healthcare: Reform of the Healthcare System: Impact and Likely Winners, which will take place on November 4, between 08:00-09:00 Beijing time. Later that afternoon, Frank Zhigang Zhao will give a company presentation to investors between 16:30-17:30.
A copy of Simcere's investor presentation will be available on the investor relations portion of the Company's Web site, located at http://www.simcere.com .
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer and
supplier of branded generic and innovative anti-cancer pharmaceuticals in
the rapidly growing China market. In recent years, Simcere Pharmaceutical
Group has focused its strategy on the development of first-to-market
generic and innovative pharmaceuticals, and has introduced a
first-to-market generic anti- stroke medication under the brand name Bicun
and an innovative anti-cancer medication under the brand name Endu. It
currently manufactures and sells 39 principal pharmaceutical products
including antibiotics, anti-cancer medication and anti-stroke medication
and is the exclusive distributor of three additional pharmaceuticals that
are marketed under its brand names. Simcere concentrates its research and
development efforts on the treatment of diseases with high incidence and/or
mortality rates and for which there is a clear demand for more effective
pharmacotherapy such as cancer, strokes, osteoporosis and infectious
diseases. For more information about Simcere Pharmaceutical Group, please
visit http://www.simcere.com .
For investor and media inquiries, please contact:
Frank Zhigang Zhao
Chief Financial Officer
Simcere Pharmaceutical Group
Tel: +86-25-8556-6666 ext. 8818
In Hong Kong:
Joseph Lo Chi-Lun
In New York:
Brunswick Group LLC
|SOURCE Simcere Pharmaceutical Group|
Copyright©2008 PR Newswire.
All rights reserved